surmount-1 trial tirzepatide non-diabetic obesity weight loss Clinical trials of subcutaneous (SURMOUNT-1, -2 and -3 𝗠𝗼𝘀𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮𝘀𝘀𝘂𝗺𝗲 𝘁𝗵𝗲 𝘄𝗲𝗶𝗴𝗵𝘁

Discussion Previous CVOTs of GLP-1RAs have demonstrated CV benefit that is not fully explained by the magnitude of weight loss, prompting calls to more directly evaluate the relationship between weight reduction and CV outcomes in this therapeutic context [20]

Your Ivm Health monthly membership provides: Unlimited 1:1 Provider Consults : Forget expensive doctor visits, our membership covers all your consultations at no extra cost

Change the injection site each time to avoid irritation

Since many people who are candidates for GLP-1s also have risk factors for cardiovascular issues, establishing this baseline is critical